Anzeige
Mehr »
Mittwoch, 18.02.2026 - Börsentäglich über 12.000 News
Noch unter 2x Umsatz bewertet - aber wie lange noch?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40B6X | ISIN: US9495031067 | Ticker-Symbol:
NASDAQ
18.02.26 | 15:33
0,269 US-Dollar
+3,74 % +0,010
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
WELLGISTICS HEALTH INC Chart 1 Jahr
5-Tage-Chart
WELLGISTICS HEALTH INC 5-Tage-Chart
ACCESS Newswire
222 Leser
Artikel bewerten:
(1)

Wellgistics Health, Inc.: Wellgistics Health Targets Expansion into $6.3 Billion Mental Health Software Market with Strategic Investment into Stealth Mental Health AI Startup

  • Previously announced partnership with Tollo Health subsidiary TolloCare adding telehealth service offering to drive Wellgistics Pharmacy prescription drug dispending of GLP-1 drugs and promote patient engagement via mental health AI software solution for compliance and to promote lifestyle changes

TAMPA, FL / ACCESS Newswire / February 18, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence ('AI') platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain, today announced that it has completed a strategic investment in a San Francisco-based mental health AI startup on the cusp of launching its service following successful beta testing. The investment fortifies the Company's strategic partnership with Tollo Health that was expanded to support Wellgistics' partnership with NFL Alumni Health.

Wellgistics is increasing its focus on patient engagement to help improve prescription drug compliance, promote complementary healthcare products such as medical food Forzet that helps improve muscle maintenance via mitochondrial biogenesis, as well as further entrench itself within its Wellgistics Pharmacy Network as local pharmacy outlets become touchpoints to provide additional products, services and support for patients. By combining digital engagement with local physical pharmacy outlets, Wellgistics aims to provide unique support for patients throughout their healthcare journey, especially patients who are initiating GLP-1 drug treatment and need assistance managing potential side effects.

According to SNS Insider, the mental health software is expected to grow from $6.3 billion in 2025 to $18.1 billion by 2033 driven by the growing adoption of digital healthcare platforms, increasing awareness of mental health conditions and the increasing adoption of software-based treatments, monitoring, and care coordination in clinical and non-clinical settings.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties' plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.'s and Wellgistics Health, Inc.'s filings with the SEC. Forward-looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Wellgistics Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/wellgistics-health-targets-expansion-into-6.3-billion-mental-health-s-1138409

© 2026 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.